Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.
Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, Gatt ME, Snir N, Magen H, Koren-Michowitz M, Herzog-Tzarfati K, Keren-Shaul H, Bornstein C, Rotkopf R, Yofe I, David E, Yellapantula V, Kay S, Salai M, Ben Yehuda D, Nagler A, Shvidel L, Orr-Urtreger A, Halpern KB, Itzkovitz S, Landgren O, San-Miguel J, Paiva B, Keats JJ, Papaemmanuil E, Avivi I, Barbash GI, Tanay A, Amit I. Ledergor G, et al. Among authors: avivi i. Nat Med. 2018 Dec;24(12):1867-1876. doi: 10.1038/s41591-018-0269-2. Epub 2018 Dec 6. Nat Med. 2018. PMID: 30523328
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A. Shimoni A, et al. Among authors: avivi i. Cancer. 2012 Oct 1;118(19):4706-14. doi: 10.1002/cncr.27418. Epub 2012 Jan 17. Cancer. 2012. PMID: 22252613 Free article. Clinical Trial.
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.
Gatt ME, Hardan I, Chubar E, Suriu C, Tadmor T, Shevetz O, Patachenco P, Dally N, Yeganeh S, Ballan-Haj M, Cohen Y, Trestman S, Muchtar E, Magen H, Jakubinsky J, Avivi I; Israeli MM study group. Gatt ME, et al. Among authors: avivi i. Eur J Haematol. 2016 Feb;96(2):136-43. doi: 10.1111/ejh.12558. Epub 2015 Apr 17. Eur J Haematol. 2016. PMID: 25827161
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E, Gatt ME, Rouvio O, Ganzel C, Chubar E, Suriu C, Tadmor T, Shevetz O, Lavi N, Shochat T, Cohen YC, Avivi I, Raanani P, Magen H. Muchtar E, et al. Among authors: avivi i. Br J Haematol. 2016 Jan;172(1):89-96. doi: 10.1111/bjh.13799. Epub 2015 Nov 16. Br J Haematol. 2016. PMID: 26567759 Free article.
Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.
Cohen YC, Zuckerman T, Yeshurun M, Perez G, Magen H, Henig I, Levi I, Shargian L, Trestman S, Rouvio U, Naparstek E, Ganon-Elazar E, Avivi I, Ram R. Cohen YC, et al. Among authors: avivi i. Ann Hematol. 2017 Feb;96(2):271-278. doi: 10.1007/s00277-016-2882-9. Epub 2016 Dec 30. Ann Hematol. 2017. PMID: 28039512
254 results